Standout Papers

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials 2023 2026 202496
  1. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (2023)
    Gil Yosipovitch, Nicholas Mollanazar et al. Nature Medicine

Immediate Impact

36 standout
Sub-graph 1 of 16

Citing Papers

The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma
2024 Standout
Therapeutic advances in rheumatoid arthritis
2024 Standout
2 intermediate papers

Works of Sheldon Wang being referenced

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
2019
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up
2019

Author Peers

Author Last Decade Papers Cites
Sheldon Wang 121 30 23 88 39 8 246
Jenny Hughes 86 31 33 67 19 9 205
P Mortureux 87 4 23 113 72 10 241
Douglas W. Lienesch 146 10 19 23 11 9 299
Martha Ann McCarty 46 25 10 69 11 9 236
Sonali J. Bracken 133 18 76 54 31 11 264
Lucia R. Wolgast 36 29 7 52 8 12 154
Marlene Garcia-Neuer 58 3 8 49 105 8 286
Madelaine Hahn 74 28 7 31 10 10 236
Susumu Kitamura 61 39 12 129 5 6 211
Malini Bhole 27 73 64 35 26 11 281

All Works

Loading papers...

Rankless by CCL
2026